StoneX Group’s Novavax NVAX Stock Holding History

StoneX Group’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-47,126	Closed	-$297K	–	985
2025 Q2	$297K	Sell	47,126 -22,762	-33%	-$151K	0.01%	667
2025 Q1	$448K	Buy	+69,888	New	+$578K	0.02%	504

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

StoneX Group's NVAX Position: Q3 2025 in Review

StoneX Group sold out of Novavax (NVAX) in Q3 2025, closing a stake of 47,126 shares — an estimated $297K sold.

StoneX Group first reported a position in NVAX in Q1 2025 and held it in 2 quarters. The position peaked at $448K in Q1 2025. 249 funds tracked by Wall St. Rank hold NVAX as of Q3 2025.

StoneX Group reported no remaining Novavax position as of Q3 2025 after selling out during the quarter.
StoneX Group sold 47,126 Novavax shares in Q3 2025, an estimated $297K.
StoneX Group first reported a position in Novavax in Q1 2025 and held it in 2 quarters.
StoneX Group's Novavax position peaked at $448K in Q1 2025.
249 funds tracked by Wall St. Rank held Novavax as of Q3 2025.

Based on StoneX Group's 13F filing for Q3 2025, filed 14 Nov 2025.